Form 4: Director Luke Evnin Sells Werewolf Therapeutics Shares

Director Luke Evnin of Werewolf Therapeutics, Inc. reported the sale of 139,803 shares of common stock via a Rule 10b5-1 trading plan.

Summary

• Director Luke Evnin sold a total of 139,803 shares of Werewolf Therapeutics (HOWL) common stock between June 1, 2026, and June 3, 2026.
• The sales were executed through various MPM BioImpact-affiliated entities.
• The transactions were conducted under a pre-established Rule 10b5-1 trading plan dated March 26, 2026.
• The weighted average sale prices ranged from $0.42 to $0.47 per share.

Sentiment

Score: 4

Explanation: StockSavvy.ai views this as neutral-to-negative; while the sales were pre-planned, the consistent selling of shares at sub-dollar prices by a director may signal a lack of confidence in near-term price appreciation.

Positives

• The sales were executed pursuant to a pre-arranged Rule 10b5-1 plan, which is a standard mechanism for insiders to sell stock without triggering concerns regarding non-public information.

Negatives

• The director reduced his indirect beneficial ownership in the company.
• The shares were sold at prices significantly below $1.00, reflecting a low valuation for the equity.

Risks

• Continued selling pressure from major institutional holders or insiders can negatively impact market sentiment and share price volatility.

Future Outlook

No specific forward-looking guidance regarding company operations was provided in this filing, as it is a disclosure of insider transaction activity.

Industry Context

StockSavvy.ai notes that insider selling in small-cap biotech firms is common, particularly when shares are trading at low valuations, often reflecting portfolio rebalancing by venture capital firms rather than a change in the company's fundamental outlook.

Comparison to Industry Standards

• The use of Rule 10b5-1 plans is the industry standard for corporate insiders to manage liquidity while maintaining compliance with SEC regulations.

Related Party Transactions

• The shares were sold by various MPM BioImpact-affiliated entities, including MPM Asset Management LLC and MPM BioVentures 2014, L.P., for which the reporting person serves as a manager or director.

Stakeholder Impact

• Shareholders may perceive the ongoing insider selling as a negative signal regarding the company's immediate growth prospects.

Next Steps

• Monitor future Form 4 filings to determine if the selling plan has been exhausted or if further divestment is scheduled.

Key Dates

Keywords

Werewolf Therapeutics, HOWL, Insider Selling, Form 4, Biotech, Rule 10b5-1